FLX Bio, Inc. (Series C)
Funding Details
- Awarder
- Inbox
- Date Award
- December 21, 2017
- Vertical
- Immuno-oncology
- Funding URL
- View Funding Page
- Funding Amount:
- $60,000,000
Company Info
- Company Description
- FLX Bio, Inc. is an immuno-oncology company focused on the discovery and development of orally-available, small molecule drugs to activate the immune system and eradicate cancer. Using its integrated immuno-oncology drug discovery platform, FLX Bio's small molecule compounds specifically target proteins and pathways important for regulatory T cells or myeloid cells within the tumor microenvironment.
- Market
- Cancer treatment
- Location
- San Francisco, CA, USA
- Coinvestors
- Celgene Corporation, The Column Group, Topspin Partners